TCW Group Inc. Has $4.47 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

TCW Group Inc. lowered its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 9.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,246 shares of the medical research company's stock after selling 3,601 shares during the quarter. TCW Group Inc.'s holdings in Natera were worth $4,474,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Chartwell Investment Partners LLC grew its position in Natera by 37.9% during the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company's stock worth $5,243,000 after purchasing an additional 11,362 shares in the last quarter. Cerity Partners LLC boosted its position in shares of Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company's stock worth $10,936,000 after buying an additional 18,316 shares during the period. Envestnet Portfolio Solutions Inc. grew its holdings in shares of Natera by 50.6% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 13,622 shares of the medical research company's stock valued at $1,475,000 after buying an additional 4,575 shares in the last quarter. Jag Capital Management LLC raised its position in Natera by 8.8% during the third quarter. Jag Capital Management LLC now owns 175,590 shares of the medical research company's stock valued at $22,291,000 after buying an additional 14,159 shares during the period. Finally, First Turn Management LLC acquired a new position in Natera during the third quarter valued at $19,760,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Insider Transactions at Natera

In other Natera news, Director Roelof Botha sold 87,473 shares of the firm's stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $169.12, for a total value of $14,793,433.76. Following the sale, the director now owns 1,224,787 shares of the company's stock, valued at $207,135,977.44. This trade represents a 6.67 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Solomon Moshkevich sold 256 shares of the company's stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total value of $30,737.92. Following the transaction, the insider now owns 111,891 shares of the company's stock, valued at approximately $13,434,752.37. This trade represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 140,601 shares of company stock worth $22,229,346. 7.60% of the stock is owned by insiders.

Wall Street Analyst Weigh In

NTRA has been the topic of several research analyst reports. Canaccord Genuity Group lifted their target price on Natera from $150.00 to $165.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Craig Hallum raised their price target on shares of Natera from $121.00 to $157.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $135.00 to $160.00 and gave the company an "overweight" rating in a research report on Wednesday, November 13th. Morgan Stanley increased their target price on shares of Natera from $132.00 to $176.00 and gave the stock an "overweight" rating in a research report on Thursday, November 14th. Finally, TD Cowen lifted their target price on shares of Natera from $155.00 to $175.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $140.59.

Natera Stock Down 0.4 %

NASDAQ NTRA traded down $0.67 during trading on Thursday, hitting $166.45. 985,417 shares of the company traded hands, compared to its average volume of 1,330,973. The company has a market capitalization of $21.97 billion, a P/E ratio of -94.57 and a beta of 1.63. The business has a fifty day simple moving average of $143.28 and a 200 day simple moving average of $124.06. Natera, Inc. has a 12 month low of $57.22 and a 12 month high of $175.63. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. During the same period last year, the business earned ($0.95) EPS. The firm's revenue was up 63.9% compared to the same quarter last year. As a group, sell-side analysts predict that Natera, Inc. will post -1.61 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.